Silence Therapeutics plc
SLNCF
$4.00
-$1.50-27.27%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 615.00K | 839.00K | 559.00K | 25.83M | 27.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 615.00K | 839.00K | 559.00K | 25.83M | 27.17M |
| Cost of Revenue | 87.00K | 172.00K | 215.00K | 2.24M | 5.82M |
| Gross Profit | 528.00K | 667.00K | 344.00K | 23.59M | 21.35M |
| SG&A Expenses | 21.27M | 21.69M | 22.34M | 24.15M | 26.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.04M | 72.45M | 82.85M | 95.82M | 99.01M |
| Operating Income | -64.43M | -71.61M | -82.29M | -69.99M | -71.84M |
| Income Before Tax | -59.95M | -75.03M | -88.60M | -64.21M | -78.74M |
| Income Tax Expenses | 2.00K | 11.00K | 11.00K | 335.00K | 383.00K |
| Earnings from Continuing Operations | -59.95 | -75.04 | -88.61 | -64.54 | -79.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.95M | -75.04M | -88.61M | -64.54M | -79.13M |
| EBIT | -64.43M | -71.61M | -82.29M | -69.99M | -71.84M |
| EBITDA | -63.94M | -71.08M | -81.74M | -69.41M | -71.26M |
| EPS Basic | -3.81 | -4.77 | -5.63 | -4.10 | -5.03 |
| Normalized Basic EPS | -0.79 | -0.98 | -1.15 | -0.83 | -1.03 |
| EPS Diluted | -3.81 | -4.77 | -5.63 | -4.10 | -5.03 |
| Normalized Diluted EPS | -0.79 | -0.98 | -1.15 | -0.83 | -1.03 |
| Average Basic Shares Outstanding | 188.94M | 188.93M | 188.93M | 188.92M | 188.75M |
| Average Diluted Shares Outstanding | 62.98M | 62.98M | 62.98M | 62.97M | 62.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |